Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.
Also called NCT04625946
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 117 participants
- Sponsor
- Registry
-
NCT04625946
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04625946. Randomized; no masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2025-07-01 (actual). Results posted on 2026-10-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Metformin
- Intervention (Behavioral)
- Recommendations for lifestyle modification.
- Intervention (Device)
- AliveCor
- Lead sponsor
- University of Michigan
Record details
- Record id
cardio:ct-nct04625946- Content hash
35aeec11df6d39f0a830d0b6f5051fccb2dcb3ba594dcf494b797696d47b68f2